TVTX Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 91% planned / 9% discretionary
Largest single sale: $2.3M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Meckler Jeffrey A 4 fills | Director | Sell 10b5-1 | 20,000 | $67.31 | $1.3M | 109,800 −15.4% of holding | |
| LYONS GARY A 2 fills | Director | Sell 10b5-1 | 5,000 | $63.37 | $316.9K | 62,400 −7.4% of holding | |
| LYONS GARY A 3 fills | Director | Sell 10b5-1 | 5,000 | $63.20 | $316.0K | 64,600 −7.2% of holding | |
| Coughlin Timothy | Director | Sell 10b5-1 | 10,000 | $50.07 | $500.7K | 56,250 −15.1% of holding | |
| Baynes Roy D. | Director | Sell 10b5-1 | 4,500 | $50.00 | $225.0K | 41,500 −9.8% of holding | |
| Coughlin Timothy | Director | Sell 10b5-1 | 3,250 | $43.49 | $141.3K | 52,250 −5.9% of holding | |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell 10b5-1 | 22,500 | $43.95 | $988.9K | 432,886 −4.9% of holding | |
| ROTE WILLIAM E. | Chief Research Officer | Sell 10b5-1 | 2,763 | $43.95 | $121.4K | 115,474 −2.3% of holding | |
| REED ELIZABETH E | Chief Legal Officer and GC | Sell 10b5-1 | 2,076 | $43.95 | $91.2K | 105,211 −1.9% of holding | |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 311 | $43.95 | $13.7K | 113,238 −0.3% of holding | |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 310 | $43.95 | $13.6K | 118,658 −0.3% of holding | |
| Baynes Roy D. | Director | Sell 10b5-1 | 4,500 | $46.65 | $209.9K | 37,500 −10.7% of holding | |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 2,181 | $46.65 | $101.7K | 118,968 −1.8% of holding | |
| REED ELIZABETH E | Chief Legal Officer and GC | Sell | 2,174 | $46.65 | $101.4K | 107,287 −2% of holding | |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2,174 | $46.65 | $101.4K | 140,684 −1.5% of holding | |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 2,174 | $46.65 | $101.4K | 113,549 −1.9% of holding | |
| REED ELIZABETH E | Chief Legal Officer and GC | Sell 10b5-1 | 20,000 | $45.00 | $900.0K | 105,211 −16% of holding | |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 20,000 | $45.00 | $900.0K | 111,473 −15.2% of holding | |
| Meckler Jeffrey A | Director | Sell 10b5-1 | 8,000 | $45.00 | $360.0K | 87,500 −8.4% of holding | |
| Baynes Roy D. | Director | Sell 10b5-1 | 9,750 | $44.22 | $431.1K | 37,500 −20.6% of holding | |
| ROTE WILLIAM E. | Chief Research Officer | Sell 10b5-1 | 9,100 | $39.09 | $355.7K | 113,987 −7.4% of holding | |
| Dube Eric M 3 fills | CHIEF EXECUTIVE OFFICER | Sell 10b5-1 | 64,000 | $41.09 | $2.6M | 440,071 −12.7% of holding | |
| REED ELIZABETH E 2 fills | Chief Legal Officer and GC | Sell 10b5-1 | 6,785 | $41.83 | $283.8K | 106,770 −6% of holding | |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 1,018 | $42.61 | $43.4K | 111,473 −0.9% of holding | |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 1,014 | $42.61 | $43.2K | 116,899 −0.9% of holding | |
| REED ELIZABETH E | Chief Legal Officer and GC | Sell 10b5-1 | 37,500 | $41.07 | $1.5M | 119,211 −23.9% of holding | |
| Baynes Roy D. 2 fills | Director | Sell 10b5-1 | 32,750 | $41.29 | $1.4M | 44,250 −42.5% of holding | |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell 10b5-1 | 21,977 | $41.07 | $902.6K | 42,353 −34.2% of holding | |
| LYONS GARY A | Director | Sell 10b5-1 | 8,000 | $41.07 | $328.6K | 57,500 −12.2% of holding | |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 7,239 | $41.93 | $303.5K | 117,913 −5.8% of holding | |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 7,215 | $41.93 | $302.5K | 112,491 −6% of holding | |
| REED ELIZABETH E | Chief Legal Officer and GC | Sell | 7,215 | $41.93 | $302.5K | 111,996 −6.1% of holding | |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 7,215 | $41.93 | $302.5K | 138,608 −4.9% of holding | |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 9 | $41.07 | $370 | 125,152 −0% of holding | |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 65 | $28.85 | $1.9K | 125,161 −0.1% of holding | |
| Baynes Roy D. | Director | Sell 10b5-1 | 10,000 | $33.00 | $330.0K | 37,500 −21.1% of holding | |
| Dube Eric M 2 fills | CHIEF EXECUTIVE OFFICER | Sell 10b5-1 | 60,000 | $30.93 | $1.9M | 457,984 −11.6% of holding | |
| REED ELIZABETH E | Chief Legal Officer and GC | Sell 10b5-1 | 10,000 | $30.00 | $300.0K | 105,211 −8.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.